Welcome to our dedicated page for MoonLake Immunotherapeutics SEC filings (Ticker: MLTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
MoonLake Immunotherapeutics filings document the regulatory record of a Cayman Islands clinical-stage biotechnology company developing sonelokimab (SLK) for inflammatory diseases. Form 8-K reports cover operating and financial results, clinical-trial disclosures for SLK programs, FDA meeting updates, Regulation FD communications, material agreements and capital-structure matters involving Class A ordinary shares.
Proxy materials describe annual meeting voting matters, including director elections, auditor ratification, executive compensation and amendments to the 2022 Equity Incentive Plan. The filing record also includes exhibits and registration-related disclosures tied to financings, governance matters and shareholder approvals.
Avoro Capital Advisors LLC and Behzad Aghazadeh filed a Schedule 13G disclosing beneficial ownership of 4,150,000 Class A ordinary shares of MoonLake Immunotherapeutics, representing 6.5% of the class. Avoro reports sole voting and sole dispositive power over these shares and states they were acquired for investment purposes on behalf of Avoro Life Sciences Fund LLC.
The filing identifies Dr. Behzad Aghazadeh as the portfolio manager and controlling person of Avoro with the same voting and dispositive powers. The reporting persons certify the holdings are held in the ordinary course of business and not for the purpose of changing or influencing control. A Joint Filing Agreement is attached as an exhibit.
On 08/05/2025 FMR LLC, the parent of Fidelity Investments, together with Abigail P. Johnson, filed Amendment No. 3 to Schedule 13G for MoonLake Immunotherapeutics (MLTX). The filing discloses beneficial ownership of 5,703,048.73 Class A shares (CUSIP 61559X104) as of 06/30/2025, representing 9.0 % of the outstanding class.
The filer reports sole voting power over 5,700,976.70 shares and sole dispositive power over 5,703,048.73 shares; there is no shared voting or dispositive power. The schedule is submitted under Rule 13d-1(b) with FMR classified as a “HC” (parent holding company/control person) and Johnson as “IN” (individual), indicating a passive investment rather than an attempt to influence control. The certification confirms the shares were acquired and are held in the ordinary course of business. No group arrangements, control-changing intentions, or additional financial terms are disclosed.